Micafungin Mylan

Micafungin, the active ingredient in Micafungin Mylan, is an echinocandin presented as an injection for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and provides prophylaxis against Candida infections in patients undergoing hematopoietic stem cell transplantation and other high‑risk settings.

GNH USA supplies Micafungin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal used to treat serious Candida infections.

- Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in immunocompromised patients. - Esophageal candidiasis: eradication of Candida infection of the esophagus in adults. - Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation: prevention of invasive candidiasis during the transplant period. - Candida peritonitis and intra‑abdominal infections: management of Candida‑related peritoneal and abdominal infections.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature during infusion. - Nausea: mild gastrointestinal discomfort reported by some patients. - Headache: occasional mild to moderate headache. - Elevated liver enzymes: transient increases in ALT or AST.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including rash, angioedema, or bronchospasm. - Hepatic failure: rare but potentially life‑threatening liver injury. - Anaphylaxis: acute, systemic allergic reaction requiring immediate medical attention.

Before initiating Micafungin therapy, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline hepatic enzymes and repeat during treatment. - Renal function assessment: evaluate kidney function, especially in patients with pre‑existing impairment. - Hypersensitivity history: avoid use in individuals with known allergy to echinocandins. - Hepatic impairment dosing: adjust or monitor closely in patients with severe liver disease. - Concomitant immunosuppressants: exercise caution when used with other agents that suppress immunity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin exposure. - Co‑administration with other echinocandins: offers no additive benefit and may increase toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): potential antagonistic effect, monitor clinical response. - Cyclosporine or tacrolimus: may require level monitoring due to possible pharmacodynamic interactions. - Warfarin: monitor INR as micafungin may affect anticoagulant control.